John Timko, MD
Psychiatry · Wyomissing, PANPI 1700992948
Payments from drug & device makers
Across 947 payments — averaging $160.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$142K
- Alkermes, Inc.$1K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$916
- plus $4K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 211 | $141,677 |
| Alkermes, Inc. | 90 | $1,429 |
| AbbVie(2 entities) | 177 | $1,223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 85 | $1,075 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 72 | $1,039 |
| Lundbeck LLC | 53 | $916 |
| Neurocrine Biosciences, Inc. | 37 | $784 |
| Teva Pharmaceuticals USA, Inc. | 18 | $486 |
| Corium, LLC | 24 | $438 |
| Vanda Pharmaceuticals Inc. | 19 | $393 |
| Axsome Therapeutics, Inc. | 21 | $381 |
| Ironshore Pharmaceuticals Inc. | 16 | $351 |
| E.r. Squibb & Sons, L.L.C. | 31 | $245 |
| Sunovion Pharmaceuticals Inc. | 21 | $228 |
| Almatica Pharma LLC | 11 | $206 |
| Supernus Pharmaceuticals, Inc. | 18 | $192 |
| Johnson & Johnson | 10 | $163 |
| Shire North American Group Inc | 9 | $137 |
| Acadia Pharmaceuticals Inc | 6 | $100 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Adlon Therapeutics L.p. | 2 | $47 |
| Vertical Pharmaceuticals, LLC | 2 | $46 |
| Merck | 2 | $36 |
| Bausch Health US, LLC | 1 | $30 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Sage Therapeutics, LLC | 1 | $18 |
| Harmony Biosciences LLC | 1 | $18 |
| Neos Therapeutics, LP | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Neuronetics, Inc. | 1 | $14 |
How this compares
$151,805 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Wyomissing
- Robert NelsonWyomissing$2.2M
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.